We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
The latest trading session saw Gilead Sciences (GILD - Free Report) ending at $77.56, denoting a -0.31% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.17%. Meanwhile, the Dow lost 0.58%, and the Nasdaq, a tech-heavy index, added 0.27%.
The the stock of HIV and hepatitis C drugmaker has risen by 3.72% in the past month, leading the Medical sector's loss of 5.22% and the S&P 500's loss of 3.95%.
The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings report is expected on November 7, 2023. In that report, analysts expect Gilead Sciences to post earnings of $1.92 per share. This would mark year-over-year growth of 1.05%. Meanwhile, the latest consensus estimate predicts the revenue to be $6.76 billion, indicating a 3.98% decrease compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.65 per share and revenue of $26.79 billion. These totals would mark changes of -8.4% and -1.8%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Gilead Sciences. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.17% higher within the past month. Right now, Gilead Sciences possesses a Zacks Rank of #2 (Buy).
Digging into valuation, Gilead Sciences currently has a Forward P/E ratio of 11.7. This indicates a discount in contrast to its industry's Forward P/E of 16.86.
Meanwhile, GILD's PEG ratio is currently 0.9. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.87.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 78, positioning it in the top 31% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
The latest trading session saw Gilead Sciences (GILD - Free Report) ending at $77.56, denoting a -0.31% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.17%. Meanwhile, the Dow lost 0.58%, and the Nasdaq, a tech-heavy index, added 0.27%.
The the stock of HIV and hepatitis C drugmaker has risen by 3.72% in the past month, leading the Medical sector's loss of 5.22% and the S&P 500's loss of 3.95%.
The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings report is expected on November 7, 2023. In that report, analysts expect Gilead Sciences to post earnings of $1.92 per share. This would mark year-over-year growth of 1.05%. Meanwhile, the latest consensus estimate predicts the revenue to be $6.76 billion, indicating a 3.98% decrease compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.65 per share and revenue of $26.79 billion. These totals would mark changes of -8.4% and -1.8%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Gilead Sciences. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.17% higher within the past month. Right now, Gilead Sciences possesses a Zacks Rank of #2 (Buy).
Digging into valuation, Gilead Sciences currently has a Forward P/E ratio of 11.7. This indicates a discount in contrast to its industry's Forward P/E of 16.86.
Meanwhile, GILD's PEG ratio is currently 0.9. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.87.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 78, positioning it in the top 31% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.